Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

Sponsor
Fundación GECP
Study ID
NCT03790397
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Osimertinib — DRUG
    Patients treated with Osimertinib within the Special Use medication Program (SUMP).

Study Details

This is a retrospective, multicenter and observational study of Osimertinib monotherapy treatment in Subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M mutation-positive who have received the treatment within the Special Use Medication Program (SUMP) in Spain.

Key Dates

Start date
Feb 26, 2019
Status verified
Jun 2022
Primary completion
Jul 15, 2019
Completion
Apr 1, 2020

Study Design

Enrollment
169 participants (actual)

Primary Outcome Measure

Progression free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]

Related Studies